Treatment of COVID-19-Induced Acute Respiratory Distress: A Phase 2 Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells
Latest Information Update: 03 Apr 2024
At a glance
- Drugs PSC-04 (Primary)
- Indications Adult respiratory distress syndrome; COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sorrento Therapeutics
- 07 Apr 2022 Planned End Date changed from 1 Mar 2022 to 1 Mar 2023.
- 07 Apr 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2022.
- 17 Nov 2021 Status changed from not yet recruiting to recruiting.